NGNE - NASDAQ
Neurogene Inc.
$26.22
+0.31%Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases. Its product candidate includes NGN-401, an investigational AAV9 gene therapy for the treatment of Rett syndrome; and NGN-101 to treat neuronal ceroid lipofuscinosis subtype 5 batten disease. The company is headquartered in New York, New York.
At a Glance
Live SnapshotNeurogene Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Declining FCF warrants attention. Investigate whether due to temporary factors or fundamental deterioration.
Working Capital Impact
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
Neurogene Inc. Cash Flow Statement
NGNE • NASDAQ
| Neurogene Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | |||||||||||||||
-90.4M | -75.1M | -36.3M | -55.2M | -50.5M | -33.3M | -8.1M | -31.6M | -50.2M | -37M | -21.9M | -23.8M | -8.7M | -7.7M | -10.5M | |
3.1M | 3.2M | 3.3M | 3.2M | 947K | 1.8M | 340K | 0.0 | 0.0 | 0.0 | 0.0 | 135.9K | 59.6K | 130.8K | 125.6K | |
0.0 | 0.0 | -105K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
14.2M | 8.3M | 1.4M | 1.3M | 896K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
-4.4M | -1.1M | -15.7M | 608K | 679K | 5.9M | -5.7M | 5.4M | 4.5M | 2.1M | 2.1M | 2.3M | -346.2K | 396.8K | 163.6K | |
268K | -6M | -4M | -2.7M | 1.6M | 966K | -2M | -5.4M | 917K | 4.7M | -546K | 3.6M | 1.1M | -45.6K | 419.5K | |
-77.2M | -70.6M | -51.4M | -52.8M | -46.4M | -24.6M | -15.4M | -31.6M | -44.7M | -30.2M | -20.3M | -17.8M | -7.9M | -7.2M | -9.8M | |
INVESTING ACTIVITIES | |||||||||||||||
-1.2M | -808K | -321K | -2.2M | -18.4M | -2.2M | -879K | -49K | -494K | -713K | -27K | -113.9K | -11.7K | -6.4K | -62.8K | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (191K) | (0.0) | (0.0) | (0.0) | (1K) | (25.9K) | (191.8K) | (0.0) | (0.0) | |
-269.5M | -198.5M | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -6M | -106.4M | -60.7M | -36.5M | -2.8M | (0.0) | (0.0) | |
284.7M | 74M | 5M | 0.0 | 0.0 | 0.0 | 0.0 | 56M | 70.5M | 59.1M | 13.2M | 13M | 0.0 | 0.0 | 0.0 | |
0.0 | 0.0 | 21M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
(14M) | -125.3M | (25.6M) | -2.2M | -18.4M | -2.2M | -688K | (56M) | (64M) | -48.1M | -47.5M | -23.6M | -2.6M | -6.4K | -62.8K | |
FINANCING ACTIVITIES | |||||||||||||||
30.5M | 189.6M | 92.3M | 0.0 | 0.0 | 77.2M | 82.2M | 602K | 438K | 71.1M | 92.9M | 47.9M | 17.8M | 0.0 | 12.1M | |
-61K | -52K | -29K | -1K | 0.0 | -49K | -9K | -32K | -15K | -4K | 0.0 | -2.6M | 2.4M | 0.0 | 0.0 | |
0.0 | -5.5M | 168K | 73K | 287K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -587.4K | 0.0 | 0.0 | |
30.4M | 184.1M | 92.5M | 66.5M | 51.1M | 77.1M | 82.2M | 570K | 423K | 71.1M | 92.9M | 45.3M | 19.6M | 0.0 | 12.1M | |
CASH FLOW SUMMARY | |||||||||||||||
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -878K | 10K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
-32.7M | -11.8M | 66.7M | 11.5M | -13.7M | 49.5M | 66.2M | 24.9M | 19.7M | -7.2M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
136.9M | 148.7M | 82M | 70.5M | 84.3M | 143.1M | 76.9M | 52M | 32.3M | 39.5M | 14.9M | 54.1M | 2M | 9.2M | 0.0 | |
104.2M | 136.9M | 148.7M | 82M | 70.5M | 192.6M | 143.1M | 76.9M | 52M | 32.3M | 39.5M | 14.9M | 54.1M | 2M | 9.2M | |
-78.4M | -71.4M | -51.7M | -55.1M | -64.8M | -26.8M | -16.3M | -31.6M | -45.2M | -30.9M | -20.3M | -17.9M | -7.9M | -7.2M | -9.9M |
SEC Filings
NGNE - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 12, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 12, 2026 | May 12, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 20, 2026 | April 20, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 16, 2026 | June 03, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 24, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 24, 2026 | March 24, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 26, 2026 | February 26, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 12, 2026 | January 12, 2026 | 2026 | |
10-Q 10-Q 2025 Q3 Q3 | November 13, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 13, 2025 | November 13, 2025 | 2025 |
Related Guides
Continue your NGNE research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.